Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
From Principles to Practice: Operationalizing the Food and Drug Administration and European Medicines Agency Guiding Principles for Artificial Intelligence in Oncology Drug Development
0
Zitationen
2
Autoren
2026
Jahr
Abstract
Artificial intelligence (AI) is transforming every stage of oncology drug development, offering unprecedented opportunities for innovation, efficiency, and patient-centered care. In January 2026, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) jointly published the “Guiding Principles of Good AI Practice in Drug Development” (“FDA-EMA Guiding Principles”). 1 These 10 principles establish a shared transatlantic framework for the responsible design, validation, and oversight of AI systems across the drug lifecycle. This article distills the regulatory intent behind the FDA–EMA Guiding Principles and translates them into operational guidance for oncology researchers, clinicians, and institutional leaders engaged in evidence generation.
Ähnliche Arbeiten
Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI
2019 · 8.402 Zit.
Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead
2019 · 8.270 Zit.
High-performance medicine: the convergence of human and artificial intelligence
2018 · 7.702 Zit.
Proceedings of the 19th International Joint Conference on Artificial Intelligence
2005 · 5.781 Zit.
Peeking Inside the Black-Box: A Survey on Explainable Artificial Intelligence (XAI)
2018 · 5.507 Zit.